Cagrilintide · long-acting amylin analog · research use only
Cagrilintide dosage, from the dose-finding trial arms.
Cagrilintide is a long-acting amylin analog — a different pathway from the GLP-1/GIP incretins it is often studied alongside — and its dosing comes from a published Phase 2 dose-finding trial rather than guesswork. This page lays out the once-weekly 0.3→4.5 mg arms the study actually used, the long half-life that supports weekly dosing, why amylin sits apart from the incretin class, and how researchers pair it with a GLP agonist — framed as a research reference, not a human dosing protocol or medical advice. Titan does not stock cagrilintide as a standalone; the in-class GLP compound it supplies is retatrutide.
The 0.3 → 4.5 mg trial arms
The once-weekly Phase 2 dose-finding trial (Lancet, Lau et al., 2021) tested cagrilintide across five subcutaneous arms — 0.3, 0.6, 1.2, 2.4 and 4.5 mg — over 26 weeks, with a stepwise escalation to reach the higher doses. Weight-loss response rose across the range, which is why later work carries the 2.4 mg dose forward in combination. Researchers model the same graded escalation rather than starting at 4.5 mg.
Cagrilintide vs retatrutide →Amylin is not an incretin
This is the point most reference pages miss: cagrilintide is an amylin analog, not a GLP-1 or GIP agonist. Amylin and the incretins act on different receptor systems, which is exactly why cagrilintide is studied in addition to a GLP agonist rather than as a substitute — the two pathways stack. If a protocol treats cagrilintide as another incretin, the mechanism is wrong from the start.
The incretin + amylin pairing →A long half-life supports weekly dosing
Cagrilintide was engineered as a long-acting amylin analog specifically so it could be dosed once weekly — its extended half-life (on the order of a week) is what separates it from native amylin, which clears in minutes. That long clock means steady-state builds over several weeks, which is why the trial held each escalation step before moving up.
Half-life context →Reconstitution math for research work
Cagrilintide's research doses span sub-milligram to low-milligram, so draws are small. As a worked example, a 5 mg vial reconstituted with 2 mL of bacteriostatic water yields 2.5 mg/mL, so 0.12 mL on a U-100 syringe draws 300 mcg and 0.96 mL draws 2.4 mg. Because the low arms are tenths of a milligram, confirm every draw against the calculator before any in-vitro modelling.
Run the numbers →Confirm identity before modelling
Amylin analogs carry a disulfide bridge and specific terminal modifications, so identity is not a formality. For cagrilintide, confirm mass-spec identity and an HPLC main-peak purity result against a stated target before building a dosing model — a mislabelled or impure lot invalidates the arithmetic. Titan documents identity and purity on a lot-matched release sheet for what it stocks; hold any out-of-catalog vendor to the same bar.
How to read a COA →Research-use framing
These figures describe doses reported in a human clinical trial, reproduced here as a research reference for in-vitro and laboratory modelling — not as instructions for human use. Cagrilintide is an investigational compound with no regulatory approval; Titan does not sell it as a standalone and supplies only research-use-only reagents, not for human or animal consumption. Nothing here is medical or dosing advice.
Research-use policy →The detail, in plain terms
The dosing reference, in one table.
Cagrilintide's dosing is anchored to a published Phase 2 dose-finding trial, which makes it a clean reference. These are the variables a researcher weighs when modelling its titration — reproduced as a reference, not a human protocol. Titan stocks retatrutide, not standalone cagrilintide.
- Compound
- Cagrilintide — long-acting amylin receptor agonist (not an incretin).
- Phase 2 dose arms
- 0.3, 0.6, 1.2, 2.4, 4.5 mg once weekly, 26 weeks (Lau et al., Lancet 2021).
- Titration
- Stepwise escalation to the target arm; 2.4 mg is the dose carried into combination work.
- Half-life
- Long-acting (~1 week order) by design — supports once-weekly dosing.
- Class note
- Amylin analog — a distinct pathway that pairs with, rather than replaces, a GLP agonist.
- Titan catalog
- Not stocked standalone. In-class GLP compound Titan sells: retatrutide 10mg, $199.99.
Questions researchers ask
Before you order.
- What doses of cagrilintide were used in the research?
- The once-weekly Phase 2 dose-finding trial (Lau et al., Lancet 2021) tested subcutaneous cagrilintide across five arms — 0.3, 0.6, 1.2, 2.4 and 4.5 mg — over 26 weeks, using a stepwise escalation to reach the higher doses. These figures are reproduced as a laboratory research reference; they are not a human dosing protocol or medical advice.
- Is cagrilintide a GLP-1 agonist?
- No — and this is the common mistake. Cagrilintide is a long-acting amylin analog, which acts on a different receptor system from the GLP-1/GIP incretins. That is precisely why it is studied in addition to a GLP agonist rather than as a replacement: the two pathways are additive, not interchangeable.
- What is cagrilintide's half-life?
- Cagrilintide was engineered as a long-acting amylin analog to allow once-weekly dosing, giving it an extended half-life on the order of about a week — in sharp contrast to native amylin, which clears in minutes. The long clock means plasma levels build to steady-state over several weeks, which is why the trial held each escalation step.
- Does Titan sell cagrilintide?
- Titan does not stock cagrilintide as a standalone product. The in-class GLP compound Titan supplies is retatrutide, a triple GLP-1/GIP/glucagon agonist, sold strictly as a research-use-only reagent. This page is an informational dosing reference and an honest pointer to what Titan actually carries, including the incretin + amylin pairing rationale.
- Is cagrilintide approved for human use?
- No. Cagrilintide is an investigational compound with no regulatory approval. The dosing figures here are reproduced strictly as a research reference for in-vitro and laboratory modelling. Titan supplies research-use-only reagents — not for human or animal consumption, diagnosis, treatment, or prevention — and nothing on this page is medical or dosing advice.